title: [Influence duration of the use of estrogens beyond the menses in estradiol IVF antagonist programming cycles].
abstract: OBJECTIVE
  To evaluate by the birth rate the impact of the number of days of estrogens continued beyond the menses in a four days estradiol IVF antagonist programming cycles.
  
  
  METHODS
  Retrospective study from September 2004 to January 2009 among women of age ranging between 25 and 38 years. Four milligrams of provames is prescribed 3 to 5 days before the theorical menses and continued until the beginning day of stimulation, which is distributed equitably between Thursday and Sunday. The birth rate is evaluated according to the number of days of estrogen continued beyond the menses within a limit from 1 to 8.
  
  
  RESULTS
  No significant difference appears neither in the duration of stimulation, in the quantity of gonadotrophin, the oocytes pick up, nor in the rate of birth between the groups.
  
  
  CONCLUSIONS
  The programming by estrogens of the antagonist IVF cycles implies a variable number of days of estrogens continued beyond the menses, which does not seem to affect the birth rate.
authors.affiliation: Clinique mutualiste La Sagesse, 3, place Saint-Guénolé, 35000 Rennes, France. anne.guivarch@orange.fr
authors.forename: A
authors.initials: A
authors.lastname: Guivarc'h-Levêque
authors.forename: L
authors.initials: L
authors.lastname: Homer
authors.forename: P-L
authors.initials: PL
authors.lastname: Broux
authors.forename: L
authors.initials: L
authors.lastname: Moy
authors.forename: G
authors.initials: G
authors.lastname: Priou
authors.forename: J
authors.initials: J
authors.lastname: Vialard
authors.forename: D
authors.initials: D
authors.lastname: Colleu
authors.forename: P
authors.initials: P
authors.lastname: Arvis
authors.forename: D
authors.initials: D
authors.lastname: Dewailly
mesh_terms: D000328:Adult; D004334:Drug Administration Schedule; D004965:Estrogen Antagonists / Q000009:adverse effects / Q000627:therapeutic use*; D004967:Estrogens / Q000008:administration & dosage* / Q000009:adverse effects / Q000494:pharmacology; D005260:Female; D005300:Fertility Agents, Female / Q000009:adverse effects / Q000627:therapeutic use; D005307:Fertilization in Vitro / Q000379:methods*; D006062:Gonadotropins / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use; D006801:Humans; D008597:Menstrual Cycle / Q000187:drug effects / Q000502:physiology; D008598:Menstruation / Q000187:drug effects* / Q000502:physiology; D010062:Ovulation Induction / Q000379:methods*; D010507:Periodicity; D011247:Pregnancy; D018873:Pregnancy Rate; D012189:Retrospective Studies; D013997:Time Factors
chemical_list: D004965:Estrogen Antagonists; D004967:Estrogens; D005300:Fertility Agents, Female; D006062:Gonadotropins